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Inflammatory bowel disease (IBD) is an autoimmune disease characterized by a chronic inflammation of the gastrointestinal tract
mucosa and is related to an abnormal immune response to commensal bacteria. Our aim of the present work has been to explore the
levels of antibodies (IgG and IgA) raised against extracellular proteins produced by LAB and its association with IBD.We analyzed,
by Western-blot and ELISA, the presence of serum antibodies (IgA and IgG) developed against extracellular protein fractions
produced by different food bacteria from the genera Bifidobacterium and Lactobacillus. We used a sera collection consisting of
healthy individuals (HC, 𝑛 = 50), Crohn’s disease patients (CD, 𝑛 = 37), and ulcerative colitis patients (UC, 𝑛 = 15). Levels of IgA
antibodies developed against a cell-wall hydrolase from Lactobacillus casei subsp. rhamnosus GG (CWH) were significantly higher
in the IBD group (𝑃 < 0.002; 𝑛 = 52). The specificity of our measurements was confirmed by measuring IgA antibodies developed
against the CWH peptide 365-VNTSNQTAAVSAS-377. IBD patients appeared to have different immune response to food bacteria.
This paper sets the basis for developing systems for early detection of IBD, based on the association of high levels of antibodies
developed against extracellular proteins from food and probiotic bacteria.
1. Introduction
Inflammatory bowel disease (IBD) is an autoimmune disease
characterized by a chronic inflammation of the gastroin-
testinal tract (GIT) mucosa. Depending on the severity and
location of the injuries, two main forms are distinguished,
Crohn’s disease (CD) and ulcerative colitis (UC). Both are
chronic disorders of unexplained origin, in which persistent
ulcerations appear in the small or large bowel mucosa.
Interestingly, genetic susceptibility only explains up to 23% of
the disease, in the case of CD (16% forUC), with the rest being
attributed to environmental factors, such as an exacerbated
response of the innate immune system to the commensal
microbiota [1].
Experiments in germ-free animals have shown that
microbial colonization is crucial in the instruction, matura-
tion, and regulation of the immune system. For instance, the
presence of Bacteroides fragilis offers protection from experi-
mental colitis, induced byHelicobacter hepaticus, in an animal
model, with this beneficial activity being dependent on the
presence of an exopolysaccharide [2]. In addition, recent
metagenomic studies with human samples have revealed
that lifestyle in developing countries is associated with an
altered microbial colonization of the human gut [3]. Indeed,
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an alteredmicrobial composition, or dysbiosis, is observed in
both mucosal and fecal samples of patients with IBD [4].
Implications of microbiota dysbiosis extend beyond the
obvious differences in microbial composition from a func-
tional and metabolic point of view. For instance, decreased
ratios between Faecalibacterium prausnitzii and Escherichia
coli in IBD patients resulted in different fecal bile acid com-
positions, with implications in the perpetuation of chronic
inflammation in IBD [5]. In the same way, Firmicutes and
Enterobacteriaceae abundances have been related to changes
in global metabolic pathways present in the gut microbiomes
of IBD patients, notably with increases in oxidative stress
pathways and decreases in carbohydrate metabolism and
amino acid biosynthesis with respect to healthy controls
[6]. For this reason, great efforts are being made in order
to understand exactly the genome complement carried by
all the microorganisms inhabiting our gut [7]. Although
gut microorganisms are essential in driving inflammation
and mucosal injuries in IBD, some other bacteria attenuate
inflammation through anti-inflammatory effects, such as cer-
tain lactic acid bacteria (LAB) or the commensal bacterium
F. prausnitzii [8–10]. Interestingly, LAB count with a long
history of safe use by human beings [11, 12].
IBD is associated with antibodies raised against extracel-
lular molecules of GIT microorganisms, such as extracellular
mannan from Saccharomyces cerevisiae (ASCA), the outer
membrane porin C protein from E. coli (anti-OmpC), or
the flagellin from members of the Clostridium cluster XIVa
[13–15]. The presence of these antibodies, together with
some specific antibodies directed against host structures
(such as antibodies to exocrine pancreas (PAB) or antineu-
trophil cytoplasmic antibodies (ANCA)), are used as serum
biomarkers of CD or UC [13, 16].
Our aim with the present work has been to explore the
levels of antibodies (IgG and IgA) raised against extracellular
proteins produced by LAB and its association with IBD. The
main results are discussed next.
2. Material and Methods
2.1. Culture Conditions and Bacterial Strains. Six bacterial
strains representing microorganisms used in human nutri-
tion, or as probiotics, were used in this study: Lactobacillus
casei subsp. rhamnosus GG (LGG), Lactobacillus acidophilus
DSM 20079T, Lactobacillus reuteri DSM 20016T, Bifidobac-
terium longum subsp. longum NCIMB 8809, Bifidobacterium
bifidum LMG 11041T, and Bifidobacterium animalis subsp.
lactis IPLA 4549. All strains were grown in MRS (de
Man, Rogosa, and Sharpe) broth (Difco, Becton Dickinson,
Franklin Lakes, NJ) supplemented with 0.05% (w/v) L-
cysteine (MRSC) (Sigma-Aldrich, St. Louis, MO). Agar (1.8%
(w/v)) was added to the broth when colony isolation was
necessary. In all cases, cultures were incubated in an anaer-
obic chamber model MG500 (Don Whitley Scientific, West
Yorkshire 100, UK) with a defined atmosphere composed of
10% (v/v) H
2
, 10% (v/v) CO
2
, and 80% N
2
.
As routine culturing, isolated bacterial colonies were
recovered on MRSC agar plates from frozen stocks stored
at −80∘C (MRSC supplemented with 40% (v/v) glycerol).
Single colonies were used for inoculatingMRSC tubes, which
were kept in the anaerobic chamber ON. FreshMRSC bottles
containing different volumes, depending on the experiment
(from 50mL to 400mL), were then inoculated from the ON
precultures (1% v/v). These cultures were incubated in the
same conditions up to early stationary phase of growth (from
12 to 48 h depending on the bacterium). Cultures were then
centrifuged (10,000×g, 30min), and the supernatants were
filtered (0.45 𝜇m) and kept for further analysis. MRSC was
used as control supernatant.
2.2. Fractionation and Separation of Extracellular Proteins.
Extracellular proteins were obtained from bacterial super-
natants following the protocol described by Sa´nchez et al.
[17]. Briefly, trichloroacetic acid (TCA) was added to the
spent supernatants at a final concentration of 6% (w/v) and
incubated ON at 4∘C. Samples were then centrifuged and
washed twice with ice-cold acetone (10,000×g, 4∘C, 10min).
Pellets were dried for one hour at 37∘C in a heat block, and
the precipitate corresponding to 50mL of culture was resus-
pended in 200𝜇L of Laemmli buffer 5X [18] with the help of
an ultrasound bath (15min) (Ultrasons-H, JP Selecta, Spain).
Samples were finally centrifuged (16,000×g, 21∘C, 5min)
to precipitate nonsolubilized proteins and volumes of 15 𝜇L
were loaded in polyacrylamide gels (12.5%) under denaturing
conditions (SDS-PAGE). Prestained Page Ruler (Thermo
Fisher Scientific, Madrid, Spain) was used as molecular mass
marker. Extracellular proteins were separated according to
Laemmli [18], in an electrophoresis buffer containing SDS
(1 g/L), TRIS (3 g/L), and glycine (15 g/L) (Sigma-Aldrich) at
pH = 8.7, under a constant current of 40mA. To visualize
proteins, gels were stained with colloidal Coomassie blue
(GelCode Blue Safe Protein Stain, Thermo Fisher Scientific),
according to the manufacturer’s instructions.
2.3. Analysis of the Serum Reactivity to Bacterial Extracellular
Proteins by Western-Blot. For detection of immunoreactive
bandswithin the different extracellular protein extracts, 40𝜇g
of protein was separated in SDS-PAGE as described above.
Proteins were transferred and immobilized onto polyvinyli-
dene fluoride (PVDF) membranes (GE Healthcare, Madrid,
Spain) for 30min under a constant voltage of 50V. PVDF
membranes were blocked with PBS (phosphate buffered
saline, Oxoid Ltd., UK) supplementedwith 0.1% (v/v) Tween-
20 (PBST) (Sigma-Aldrich) and with 5% (w/v) skimmed
milk (PBST-L) (Oxoid Ltd.) for 3 h at room temperature.
Membranes were washed twice and individual sera were
diluted to 1 : 100 in PBST-L and incubated over the mem-
branes (ON, 4∘C) with slight agitation. Membranes were
then washed 4 times with PBST and incubated for 1 h with
a secondary antibody conjugated to horseradish peroxi-
dase (horseradish peroxidase-conjugated anti-human IgA or
IgG (Sigma-Aldrich)), diluted to 1 : 2,000 in PBST-L. For
detection of immunoreactive bands, a commercial solution
containing the chromogenic reagents chloronaphthol and
diaminobenzidine (CN/DAB Substrate Kit, Thermo Fisher
Scientific) was used.
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Table 1: Demographic and clinical parameters of UC patients.
Clinical parameters n = 16
Men/women 11/7
Age, mean ± sd 45.25 ± 16.89
Disease duration, mean ± sd 8.37 ± 8.57
Age at onset, mean ± sd 36.88 ± 16.79
Familial history 5 (31.3)
Location
Extensive 9 (56.3)
Left-sided 2 (12.5)
Proctitis 5 (31.3)
Extraintestinal manifestations
Arthritis 4 (25.0)
Dermatological affection 4 (25.0)
Values are n or n (%), unless stated otherwise.
Table 2: Demographic and clinical parameters of CD patients.
Clinical parameters n = 37
Men/women, n 23/14
Age, mean ± sd 42.89 ± 12.89
Disease duration, mean ± sd 10.08 ± 8.56
Age at onset, mean ± sd 32.78 ± 12.41
Familial history 8 (21.6)
Location
Ileum 11 (29.7)
Colon 5 (13.5)
Ileum + colon 20 (54.1)
Upper gastrointestinal 1 (2.7)
Extraintestinal manifestations
Arthritis 14 (37.8)
Dermatological affection 9 (24.3)
Perianal disease 12 (32.4)
Fistula 15 (40.5)
Values are n or n (%), unless stated otherwise.
Detection of immunoreactive bandswas performed using
a collection of sera and consisted of 50 samples from
healthy individuals, 37 samples from individuals with CD,
and 15 samples from individuals with UC. Approval for the
study was obtained from the Regional Ethics Committee
for Clinical Investigation (Comisio´n Asesora de Bioe´tica del
Principado de Asturias; Servicio de Salud del Principado
de Asturias) and all determinations were performed with
fully informed written consent. This collection is deposited
in the “Coleccio´n del Registro Nacional de Biobancos”,
Ref. C.0001263 (https://sede.isciii.gob.es/). Demographic and
clinical parameters of the UC and CD patients are shown in
Tables 1 and 2.
2.4. Purification of the Cell-Wall Hydrolase of LGG. Around
one milligram of extracellular protein fraction from LGG
was separated in polyacrilamide gels, as described before,
using multiple wells. CWH is the only extracellular protein
of LGG separated in the gel range of 70–80 kDa, so this
zone was cut out of the gels with the help of the pre-stained
molecular mass marker, containing a red-labelled band of
70 kDa. Gel slides were placed into dialysis membranes with
a cut-off of 8 kDa and 3mL of electrophoresis buffer were
added. Dialysis membranes were set in the electrophoresis
chamber and the system was maintained for one hour at a
constant voltage of 170V. Following this procedure, CWH
was electroeluted from the gel slides. CWH protein, already
in solution, was concentrated in a vacuum device at room
temperature (Concentrator 5301, Eppendorf AG, Germany),
and finally dialyzed against PBS for 24 h at 4∘C (Tube-
O-dialyzer devices, G-biosciences, cut-off 1 kDa). Protein
concentration was determined by the bicinchoninic acid test
(BCA kit, Thermo Fisher Scientific), using a series of bovine
serum albumin standards.
2.5. ELISAs against the Cell-Wall Hydrolase of LGG. Specific
IgG and IgA antibodies developed against the CWH of LGG
were titrated in all the sera. Two 𝜇g of CWH, purified as
described above, was dissolved in PBS and coated on the
surface of a 96 well plate (Nunc) 1 h at 37∘C and then ON
at 4∘C. Wells were washed twice with 300 𝜇L of PBST and
blocked with 200𝜇L of 1% (w/v) bovine serum albumin in
PBS (1 h at RT and with gentle shaking). Wells were washed
twice again with 300 𝜇L of PBST and incubated with 200𝜇L
of the sera dilutions, made with PBST, for 2 h at RT. The
dilutions tested were 1 : 100, 1 : 250, 1 : 500, 1 : 1,000, 1 : 2,500,
1 : 5,000, and 1 : 10,000. Wells were washed twice with 300 𝜇L
of PBST and incubated with 100 𝜇L of a secondary antibody
dilution in PBST (1 : 10,000) (anti-human IgG or anti-human
IgA conjugated with horseradish peroxidase, Sigma-Aldrich)
in PBST, for 1 h at RT. Finally, wells were washed twice with
PBST and 100 𝜇L of the chromogenic substrate ultra-TMB-
ELISA (Thermo Fisher Scientific) was added and incubated
for 20min at RT. Reactions were stopped with 2M H
2
SO
4
and the Abs
450
of the wells measured.The titer of each serum
was defined as the last dilution of serum that gave a positive
reaction (Abs
450
threshold = 0.300).
2.6. CWH Bioinformatic Analysis and Synthesis of a Specific
Peptide. Homology searches using the CWH amino
acid sequence (gi|258507319; ref|YP 003170070.1) were
performed using the BlastP algorithm implemented
at the National Center for Biotechnology Information
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) against the curated,
nonredundant “nr” database. Homologous proteins present
in other species belonging to the Firmicutes phylum were
retrieved and aligned, and the comparative analysis allowed
us to identify a specific peptide present in the CWH protein
from L. casei subsp. rhamnosus that was not present in other
intestinal or food bacteria species (query performed on
February 24, 2014). Two mg of the specific CWH peptide
(CWHp) was chemically synthesized by the company
Genecust (Luxembourg), with a minimum purity of 95%.
2.7. CWHp against the Peptide ELISAs. Antibodies developed
against the CWHp and present in the following sera C72,
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(1)
(2)
(3)
(4)
(5)
Lactobacillus acidophilus
Lactobacillus casei subsp. rhamnosus
Lactobacillus reuteri
Bifidobacterium bifidum
Bifidobacterium longum subsp. longum
(6) Bifidobacterium animalis subsp. lactis
1 2 3 4 5 6
(a)
C68 IgA C65 IgA P47 IgA P30 IgA
P40 IgA P31 IgA P19 IgA P38 IgA
1 → 6 1 → 6 1 → 6 1 → 6
1 → 6 1 → 6 1 → 6 1 → 6
(b)
Figure 1: (a) Immunoreactive bands corresponding to antibodies present in the sera of healthy controls or IBD patients raised against
the extracellular proteins of the bacterial strains used in this study. (b) Western blotting analysis showing different patterns of sera
immunoreactivity against extracellular proteins produced by the strains used in this study (C# healthy controls; P# IBD patients). In all cases,
a secondary anti-human IgA antibody, HRP conjugated, was used. The order of the lanes (lines 1 to 6) correspond to that of the SDS-PAGE.
C65, C49, C59, P8, P39, P34, and P20 were determined by
ELISA as described before. These sera were chosen as being
representative for the specificCWHanti-IgA/anti-IgG values.
Five 𝜇g of the peptide was coated on the surface of 96-
well plates (Nunc), and the following serum dilutions were
tested for titration: 1 : 100, 1 : 250, 1 : 500, 1 : 1,000, 1 : 2,500,
1 : 5,000, and 1 : 10,000. The rest of the procedure was exactly
as described for the CWH.
2.8. Statistical Methods. In order to evaluate and analyze
distribution of data, the following tests were applied: the
Runs test, Leve`ne’s test, and the Kolmogorov-Smirnov test.
The nonparametric Kruskal-Wallis test was used for median
comparison between groups (healthy controls, CD, UC, and
IBD). All tests were performed using SPSS v18.0 software.
3. Results and Discussion
Several immunological studies have shown that the human
immune system, in the framework of IBD, reacts differentially
against many of the microorganisms composing our gut
microbiota by producing specific IgA and IgG responses such
as ASCA [19]. Experimental evidence points to extracellular
proteins secreted by probiotic bacteria as molecular effectors
of their beneficial effects on the human host [20–23]. Specific
antigens developed against this subset of proteins, which are
normally consumed with fermented and functional foods,
may be related to IBD.
Susceptibility to IBD has been associated with the so-
called leaky gut syndrome (LGS), in which a decrease in the
gut epithelial barrier led to an increase of antigens from food
and bacteria from the gut lumen leaking into the body [24].
Also, it is known that excessive bacterial translocation in CD
is a key factor in the development of the disease, in which
certain genetic mutations affect the autophagy pathway [25].
In fact it has been proposed that antigens belonging to com-
mensal microbiota could interact with the immune system
evoking antibody-driven inflammatory responses [26]. In a
healthy gut, the immune system reacts against commensal
microbiota by producing antibodies, notably secretory IgA
[27, 28].
Extracellular proteins from the bacteria strains used in
this study, all of them representative of microorganisms
used as probiotics or in human nutrition, were immobi-
lized on PVDF membranes and submitted to immunoblot
analysis. Incubation with pools of sera of the three dif-
ferent groups (HC, CD, and UC), showed the presence of
different immunoreactive bands when membranes where
developed using an anti-human IgA antibody conjugated
with horseradish peroxidase (Figure 1(a)). The presence of
strong immunoreactive bands prompted us to hybridize
immobilized extracellular protein extracts using all the sera
individually (Figure 1(b)). This analysis revealed that a pro-
tein in the molecular mass range of 70 kDa, produced by
LGG, displayed a wide range of immunoreactivity among all
the tested sera, including healthy controls and IBD patients.
This protein was identified by peptide mass fingerprinting as
the homologous to L. casei cell-wall hydrolase, also known
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Figure 2: Distribution of the specific anti-CWH titers (IgG and IgA) of all the sera divided into two groups (HC: healthy controls, IBD:
inflammatory bowel disease) ( ∗∗𝑃 < 0.01).
as P-75. This is a cell-wall hydrolase able to hydrolyze
muropeptides from L. casei [29]. In addition, CWH has an
affinity for molecules present on intestinal surfaces, such
as mucin and fibronectin [30]. CWH and P-40, being two
of the most abundantly secreted proteins by LGG with the
glyceraldehyde-3-phosphate dehydrogenase [31], accomplish
different functions in gut homeostasis, such as reduction
of inflammatory damages and increases of transepithelial-
resistance by increasing tight-junction protein production
[32, 33].
At this point, our results strongly suggested that the levels
of specific anti-CWH IgAs were increased in the IBD sera.
As Western-blot is very limited for antibody quantification,
we purified enough amounts of CWH following the proce-
dure described in the Material and Methods section. Once
CWH was purified, and after verifying its purity by SDS-
PAGE, the protein was used for the coating of 96-well plates
and for quantifying the levels of specific antibodies present in
the sera collection. After incubation of the different sera with
the coated CWH, we used two types of secondary antibodies
for detection of different antibody isotypes specifically devel-
oped against CWH, anti-human IgG, and anti-human IgA.
While levels of specific IgGs remained constant between
the two populations (healthy controls versus IBD patients)
with the exception of some outlier, levels of anti-CWH IgA
were significantly higher in the IBD sera (Figure 2). However,
when the IBD patients were divided in CD and UC and
the levels of the anti-CWH IgA were analyzed again, titers
were unable to differentiate between the two conditions
(Figure 3). It is known that IBD patients showing high serum
reactivity against gut microbes have the most complicated
disease phenotypes13. In this context we can mention ASCA,
p-ANCA, and anti-flagellin antibodies, with the latter being
even more frequent in other inflammatory disorders such as
irritable bowel syndrome (IBS) [16]. In a study conducted by
Furrie et al. [26], UC patients showed a higher IgG response
than CD patients. Contrary to this work, no differences in the
anti-CWH IgG titers were found between the IBD group and
the HC group, even if IBD patients were divided into UC and
CD subgroups.
In a step forward, we compared the amino acidic
sequence of the CWH protein from LGG against the nonre-
dundant protein database at the NCBI servers, in order to
determine whether the anti-CWH antibodies were or were
not specific to this protein. A BLAST analysis allowed us to
identify a 13-mer peptide whichwas only present in the CWH
from L. casei subsp. rhamnosus 365-VNTSNQTAAVSAS-377.
Chemical synthesis of the peptide allowed us to measure the
specific antibodies (anti-IgG and anti IgA) present in the
different sera. In this case, we used the sera corresponding to
these healthy controls/IBD patients C49, C59, C65, C72, P8,
P20, P34, and P39. These sera were chosen as representative
of the specific CWH anti-IgA and anti-IgG titer distribution.
IgA titers against the specific CWH peptide, although lower
than those measured for the whole CWH protein, were also
higher in the IBD sera and lower in the healthy controls
(Table 3).
Surprisingly, titers corresponding to the specific CWH-
peptide IgG antibodies were zero in all the sera, suggesting
that they have been developed against homologous surface
proteins of other Gram positive bacteria. In this sense,
presence of certain enteropathogens, notably infection by
Mycobacterium avium subsp. paratuberculosis, has been pro-
posed as a trigger factor for IBD, although controversial data
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Figure 3: Distribution of the specific anti-CWH titers (IgG and IgA) of all the sera assayed taking into account three groups: healthy controls
(HC), Crohn’s disease (CD), and ulcerative colitis (UC).
Table 3: Comparison between the titers values obtained in different
sera (C#: healthy controls, P#: IBD patients) using different target
proteins (CWH: purified cell wall hydrolase, CWHp: specific CWH
peptide) and different secondary antibodies (Anti-human IgA and
IgG). Results are expressed as the median of 3 independent mea-
sures.
Patient Anti CWHp-IgG(antiCWH IgG)
Anti CWHp-IgA
(antiCWH IgA)
C72 0 (2,500) 250 (2,500)
C65 0 (500) 500 (1,000)
P34 0 (2,500) 250 (2,500)
P20 0 (500) 1,000 (10,000)
C49 0 (250) 500 (1,000)
C59 0 (250) 500 (1,000)
P39 0 (500) 500 (2,500)
P8 0 (500) 1,000 (2,500)
have been published so far [34]. Also, increased levels of
antibodies developed against proteins secreted by M. avium
subsp. paratuberculosis in Japanese patients suffering from
CD have been reported [35].
Why levels of IgA antibodies against extracellular pro-
teins produced by gut bacteria are more elevated in IBD
patients? It is known that increased gut permeability may
correlate with IBD susceptibility/risk. This elevated passage
of bacterial antigens in the intestinal mucosa may lead to
a concomitant increase in the immune response through
specific antibody production for compensating this failure
in the barrier function of the gut epithelium [24]. In the
case of familial Mediterranean fever (FMF), which is another
autoimmune disease with inflammatory conditions and skin
manifestations, levels of IgG antibodies against common gas-
trointestinal bacteria such as Bacteroides sp., Parabacteroides
sp., E. coli, and Enterococcus sp. were increased [36].
4. Concluding Remarks
Our experiments showed that IgA antibodies specifically
developed against an extracellular protein of L. casei are
associated with IBD. Quantification of antibodies against
extracellular proteins from food and probiotic bacteria may
be helpful in the early diagnosis of IBD.Therefore, our results
suggest that anti-CWH IgA levels have great potential for
being used for early detection of CD and UC; however,
validation of these findings in different populations of greater
sample size would be required, together with the identifica-
tion of other extracellular protein targets present in food and
probiotic bacteria.
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